Up-regulation of urokinase-type plasminogen activator in squamous cell carcinoma of human larynx

British Journal of Cancer

Volumn 74, Issue 8, 1996, Pages 1168-1174

  Parolini, S ^a   Flagiello, D ^a   Cinquetti, A ^a   Gozzi, R ^a   Cristini, S ^a   Cappiello, J ^b   Nicolai, P ^b   Rusnati, M ^a   Presta, M ^a   Molinari Tosatti, M P ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

^b UNIVERSITY OF BRESCIA   (Italy)

Author keywords

Immunohistochemistry; In situ hybridisation; Larynx carcinoma; Metastasis; Urokinase

Indexed keywords

CHROMOGENIC SUBSTRATE; MESSENGER RNA; TUMOR PROTEIN; UROKINASE;

ARTICLE; CANCER INVASION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBROBLAST; GEL ELECTROPHORESIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LARYNX CARCINOMA; LYMPH NODE METASTASIS; MACROPHAGE; MAJOR CLINICAL STUDY; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; STROMA CELL; TUMOR BIOPSY; TUMOR CELL;

EID: 0011489870     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.512     Document Type: Article

References (47)

1. ANTONELLI AR, NICOLAI P, CAPPIELLO J, PERETTI G, MOLINARI TOSATTI MP, ROSA D, GRIGOLATO PG, FAVRET M AND MAROCCOLO D. (1991). Basement membrane components in normal, dysplastic, neoplastic laryngeal tissue and metastatic lymph nodes. Acta Otolaryngol. 111, 437-443.
2. CAMIOLO SM, MARKUS G, EVERS JL, HOBIKA GH, DEPASQUALE JL, BECKLEY S AND GRIMALDI JP. (1981). Plasminogen activator content of neoplastic and benign human prostate tissues: fibrin augmentation of an activator activity. Int. J. Cancer, 27, 191-198.
3. CAMIOLO SM, MARKUS G, ENGLANDER LS, SIUTA MR, HOBIKA GH AND KOHGA S. (1984). Plasminogen activator content and secretion in explants of neoplastic and benign human prostate tissues. Cancer Res., 44, 311-318.
4. CLAYMAN G, WANG SW, NICOLSON GL, EL-NAGGAR A, MAZAR A, HENKIN J, BLASI F, GOEPFERT H AND BOYD DD. (1993). Regulation of urokinase-type plasminogen activator expression in squamous-cell carcinoma of the oral cavity. Int. J. Cancer, 54, 73-80.
5. COLOMBI M, BARLATI S, MAGDELENAT H AND FISZER-SZAGARZ B. (1986). Relationship between multiple forms of plasminogen activator in human breast tumors and plasma and presence of metastasis in lymph nodes. Cancer Res., 44, 2971-2975.
6. COLOMBI M, MORO L, ZOPPI N, GHINELLI A AND BARLATI S. (1991). Altered fibronectin mRNA splicing in skin fibroblast from Ehlers - Danlos syndrome patients: in situ hybridization analysis. Cell Biol. Int. Rep., 15, 1195-1205.
7. COLOMBI M, MORO L, ZOPPI N AND BARLATI S. (1993). Quantitative evaluation of mRNAs by in situ hybridation and image analysis: principles and applications. DNA Cell Biol., 12, 629-636.
8. CORASANTI JG, CFLIK C, CAMIOLO SM, MITTELMAN A, EVERS JL, BARBASCH A, HOBLKA GH AND MARKUS G. (1980). Plasminogen activator content of human colon tumors and normal mucosae: Separation of enzymes and partial purification. J. Natl Cancer Inst., 65, 345-351.
9. DANØ K, ANDREASEN PA, GRØNDAHL-HANSEN J, KRINSTENSEN JP, NIELSEN LS AND SKRIVER L. (1985). Plasminogen activators, tissue degradation and cancer. Adv. Cancer Res., 44, 139-266.
10. DE BRUIN PAF, VERSPAGET HW, GRIFFERON G, NAP M, VERHEIJEN JH AND LAMERS CBHW. (1987a). Plasminogen activator activity and composition in human colorectal carcinomas. Fibrinolysis, 1, 57-62.
11. DE BRUIN PAF, GRIFFERON G, VERSPAGET HW, VERHEIJEN JH AND LAMERS CBHW. (1987b). Plasminogen activators and tumour development in the human colon: activity levels in normal mucosa, adenomatous polyps and adenocarcinomas. Cancer Res., 47, 4654-4657.
12. GOLDBERG AR. (1974). Increased protease levels in transformed cells: a casein overlay for the detection of plasminogen activator production. Cell, 2, 95-102.
13. GRØNDAHL-HANSEN J, CHRISTENSEN IJ, ROSENQUIST C, BRUNNER N, MOURIDSEN HT, DANØ K AND BLICHERT-TOFT M. (1993). High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res., 53, 2513-2521.
14. HASUI Y, SUZUMINYA J, MARUTSUKA K, SUMIYOSHI A, HASHIDA S AND ISHIKHAWA EI. (1989). Comparative study of plasminogen activators in cancers and normal mucosae of human urinary bladder. Cancer Res., 49, 1067-1070.
15. HASUI Y, MARUTSUKA K, SUZUMIYA J, KITAOTA S, OSADA Y AND SUMIYOSHI A. (1992). The content of urokinase-type plasminogen activator antigen as a prognostic factor in urinary bladder cancer. Int. J. Cancer, 50, 871-873.
16. 125I-labeled RNA. J. Histochem. Cytochem., 26, 677-679.
17. HEARING JV, LAW LW, CORTI A, APPELLA E AND BLASI F. (1988). Modulation of metastatic potential by cell surface urokinase of murine melanoma cells. Cancer Res., 48, 1270-1278.
18. JANICKE F, ACHMITT M, HAFTER R, HOLLRIEDER A, BABIC R, ULM K, GOSSNER W AND GRAEFF H. (1990). Urokinase-type plasminogen activator (uPA) antigen is a predictor of early relapse in breast cancer. Fibrinolysis, 4, 69-78.
19. JANICKE E, SCHMITT M, MOUIWA M, CHUCHOLOWSKI N, PACHE L AND GRAEFF M. (1992). Tumor-associated urokinase-type plasminogen activator: biological and clinical significance. Biol. Chem. Hoppe-Seyler, 373, 611-622.
20. KOHGA S, HARVEY S AND MARKUS G. (1985). Localization of plasminogen activators in human colon cancer by immunoperoxidase staining. Cancer Res., 45, 1787-1796.
21. KRISTENSEN P, PYKE C, LUND LR, ANDREASEN PA AND DANØ K (1990). Plasminogen activator inhibitor-type 1 in Lewis lung carcinoma. Histochemistry, 93, 559-566.
22. MARKUS G, TAKITA II, CAMIOLO SM, CORASANTI JG, EVERS JI AND HOBIKA GH. (1980). Content and characterization of plasminogen activators in human lung tumors and normal lung tissue. Cancer Res., 40, 841-848.
23. MIGNATTI P, ROBBINS E AND RIFKIN DB (1986). Tumor invasion through the human amniotic membrane: requirement for a proteinase cascade. Cell, 47, 487-498.
24. MIGNATTI P AND RIFKIN DB. (1993). Biology and biochemistry of proteinases in tumor invasion. Physiol. Rev., 73, 161-195.
25. MORO L, COLOMBI M, CRESPI S, DI LERNIA R AND BARLATI S. (1990). Study of fibronectin expression in tumour cells by dot-blot and in situ hybridization: quantitative evaluation by image analysis. Cell Biol. Int. Rep., 14, 701-715.
26. MORO L, COLOMBI M, MOLINARI TOSATTI MP AND BARLATI S. (1992). Study of fibronectin mRNA in human laryngeal and ectocervical carcinomas by in situ hybridization and image analysis. Int. J. Cancer, 51, 692-697.
27. NEUMAN T, STEPHENS RW, SALONEN EM, TIMMUSK T AND VAHERI A. (1989). Induction of morphological differentiation of human neuroblastoma cells is accompanied by induction of tissue-type plasminogen activator. J. Neurosci. Res., 23, 274-281.
28. NISHINO N, AOKI K, TOKURA Y, SAKAGUCHI S, TAKADA Y AND TAKADA A. (1988). The urokinase type of plasminogen activator in cancer of digestive tracts. Thromb. Res., 50, 527-535.
29. OSSOWSKI L. (1988). In vivo invasion of modified chorioallantoic membrane by tumor cells: the role of cell surface-bound urokinase. J. Cell Biol., 107, 2437-2445.
30. OSSOWSKI L AND REICH E. (1993). Antibodies to plasminogen activator inhibit human tumor metastasis. Cell, 35, 611-619.
31. OSSOWSKI L, UNKELESS JC, TOBIA A, QUIGLEY JP, RIFKIN DB AND REICH E. (1973). An enzymatic function associated with transformation of fibroblasts by oncogenic viruses. II Mammalian fibroblast cultures transformed by DNA and RNA tumor viruses. J. Exp. Med., 137, 112-126.
32. PRESTA M, MAIER JAM AND RAGNOTTI G. (1989). The mitogenic signaling pathway but not the plasminogen activator-induced pathway of basic fibroblast growth factor is mediated through protein kinase C in fetal bovine aortic endothelial cells. J. Cell Biol., 109, 1877-1884.
33. PYKE C, KRISTENSEN P, RALFKIAER E, GRØNDAL-HANSEN J, ERIKSEN J, BLASI F AND DANO H. (1991). Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. Am. J. Pathol., 138, 1059-1067.
34. RIJKEN DC AND COLLEN D. (1981). Purification and characterization of the plasminogen activator secreted by human melanoma cells in culture. J. Biol. Chem., 256, 7053-7041.
35. SAKSELA O AND RIFKIN DB. (1988). Cell-associated plasminogen activation: regulation and physiological functions. Annu. Rev. Cell Biol., 4, 93-126.
36. SAPPINO A-P, BUSSO N, BELIN D AND VASSALLI J-D. (1987). Increase of urokinase-type plasminogen activator gene expression in human lung and breast carcinomas. Cancer Res., 47, 4043-4046.
37. SAPPINO A-P, BELIN D, HUARTE J, HIRSCHEL-SCHOLZ S, SAURAT J-H AND VASSALLI J-D. (1991). Differential protease expression by cutaneous squamous and basal cell carcinomas. J. Clin. Invest., 88, 1073-1079.
38. SCHMITT M, JANICKE F AND GRAEFF H. (1990). Tumor-associated fibrinolysis: the prognostic relevance of plasminogen activators uPA and tPA in human breast cancer. Blood Coagul. Fibrinol., 1, 695-702.
39. SIM P-S, STEPHENS RW, FAYLE DRH AND DOE WF. (1988). Urokinase-type plasminogen activator in colorectal carcinomas and adenomatous polyps: quantitative expression of active and proenzyme. Int. J. Cancer, 42, 483-488.
40. SKRIVER L, LARSSONN LI, KIELBERG V, NIELSEN LS, ANDERSONS PB, KRISTENSENS P AND DANØ K. (1984). Immunocytochemical localization of urokinase-type plasminogen activator in Lewis lung carcinoma. J. Cell. Biol., 99, 752-757.
41. SUGIMIRA MD, KOBAYASHI H, KANAYAMA N AND TOSHIHIKO T. (1992). Clinical significance of urokinase-type plasminogen activator (uPA) in invasive cervical cancer of the uterus. Oncology, 46, 330-336.
42. SUMIYOSHI K, BABA S, SAKAGUCHI S, URANO T, TAKADA Y AND TAKADA A. (1991). Increase in levels of plasminogen activator and type-1 plasminogen activator inhibitor in human breast cancer: Possible roles in tumor progression and metastasis. Thromb. Res., 63, 59-71.
43. SUMIYOSHI K, SERIZAWA K, URANO T, TAKADA Y, TAKADA A AND BABA S. (1992). Plasminogen activator system in human breast cancer. Int. J. Cancer, 50, 345-348.
44. UNKELESS JC, DANØ K, KELLERMAN GM AND REICH E. (1974). Fibrinolysis associated with oncogenic transformation. Partial purification and characterization of the cell factor, a plasminogen activator. J. Biol. Chem., 249, 4295-4305.
45. VASSALLI J-D AND BELIN D. (1987). Amilorde selectivity inhibits the urokinase-type plasminogen activator. FEBS Lett., 214, 187-191.
46. WILSON EL, BECKER MLB, HOAL EG AND DOWDLE EB. (1980). Molecular species of plasminogen activators secreted by normal and neoplaslic human cells. Cancer Res., 40, 933-938.
47. WHITNEY CW, SATYASWAROOP PG AND MORTEL R. (1985). Plasminogen activator activity in human endometrial carcinoma. Gynecol. Oncol., 22, 97-104.